What is lean mass preservation?
Lean mass preservation is the research objective of maintaining skeletal muscle and other fat-free tissue during pharmacologically induced weight loss. This page defines the term, its identifiers, and the study designs i
What is lean mass preservation?
Lean mass preservation is the formal research term for maintaining fat-free mass — principally skeletal muscle — while body fat is reduced during a weight-loss intervention. Synonyms in the literature include fat-free mass preservation, muscle mass sparing, and lean-tissue retention. The term is a study endpoint rather than a compound class: it describes what a co-administered agent or regimen is being tested to do alongside a primary weight-loss drug, not a molecular entity with a sequence, formula, or molecular weight of its own.
The work centres on the myostatin/activin signalling axis and its interaction with incretin receptor pharmacology, particularly glucagon-like peptide-1 receptor (GLP-1R) agonism [1][2].
Research Studies
Semaglutide and lean mass in adults with obesity
Semaglutide, a GLP-1 receptor agonist, is the background therapy in the studies below. GLP-1-based therapies have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery, but they have revealed limitations including weight-loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation [1]. Those limitations are the stated rationale for next-generation approaches, including combinations intended to preserve lean tissue [1].
Trevogrumab and lean mass preservation with semaglutide in adults with obesity
Trevogrumab is an experimental drug being tested in combination with semaglutide (Wegovy®) in adult patients with obesity [2]. The registered study title explicitly names fat loss and lean mass preservation as outcomes [2]. The trial is divided into Part A, Part B, and Part C, in which different study drugs are tested [2].
Garetosmab and lean mass preservation with semaglutide in adults with obesity
Garetosmab is a second experimental drug tested in the same programme, alone or in combination with trevogrumab, alongside semaglutide [2]. The study aims in Part B and Part C are to assess safety and effectiveness of the study drug when combined with Wegovy in participants with obesity [2].
Study population and design in NCT06299098
The programme separates populations by part. Part A is focused on healthy participants; Parts B and C are focused on participants with obesity [2]. Part A aims to assess safety and tolerability of the study drug in healthy participants, while Parts B and C aim to assess safety and effectiveness when combined with Wegovy [2].
| Study part | Population | Primary aim |
|---|---|---|
| Part A | Healthy participants | Safety and tolerability of the study drug [2] |
| Part B | Participants with obesity | Safety and effectiveness combined with Wegovy [2] |
| Part C | Participants with obesity | Safety and effectiveness combined with Wegovy [2] |
Multi-receptor agonists and next-generation metabolic modulators
Existing reviews have focused predominantly on approved GLP-1 receptor agonists, with limited synthesis of emerging multi-receptor agonists, oral formulations, and body composition outcomes [1]. The same review frames the field as moving toward multi-receptor agonists and next-generation metabolic modulators, and notes that obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050 [1].
Weight regain after discontinuation and the case for lean mass preservation
Weight regain upon discontinuation of GLP-1-based therapy is one of the limitations cited as motivating next-generation approaches [1]. Lean mass preservation is studied in that context — as a co-primary or secondary objective layered onto an existing weight-loss backbone rather than as a standalone intervention [1][2].
What the current evidence does and does not show
The evidence block for this page contains a review of obesity pharmacotherapy and a registered clinical trial record [1][2]. It does not contain completed efficacy results for trevogrumab or garetosmab, and no animal-only or in vitro data on lean mass preservation are supplied here. Claims about magnitude of lean mass retention, effect sizes, or comparative performance between agents are therefore not made on this page.
Identifiers and terminology
Lean mass preservation has no CAS number, sequence, or molecular weight because it is an outcome definition. The compounds studied under this heading do have registry identifiers, and the trial itself is identified as NCT06299098 [2].
If you are reading this for personal health reasons
The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies
- [2] A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation